m-PEG11-Br

CAS No. 1258596-39-2

m-PEG11-Br( —— )

Catalog No. M23430 CAS No. 1258596-39-2

m-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 29 In Stock
50MG 32 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    m-PEG11-Br
  • Note
    Research use only, not for human use.
  • Brief Description
    m-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    m-PEG11-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • In Vitro
    PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PEGs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1258596-39-2
  • Formula Weight
    579.52
  • Molecular Formula
    C23H47BrO11
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCBr
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
  • Boc-NH-O-C1-NHS este...

    Boc-NH-O-C1-NHS ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.

  • TCO-NHS ester

    TCO-NHS ester is a alkyl/ether-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules.

  • MS4078

    MS4078 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=11 nM).